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Background: Energy homeostasis is regulated by the hypothalamus but fails when animals are fed a high-fat diet
(HFD), and leptin insensitivity and obesity develops. To elucidate the possible mechanisms underlying these effects,
a microarray-based transcriptomics approach was used to identify novel genes regulated by HFD and leptin in the
mouse hypothalamus.
Results: Mouse global array data identified serpinA3N as a novel gene highly upregulated by both a HFD and leptin
challenge. In situ hybridisation showed serpinA3N expression upregulation by HFD and leptin in all major
hypothalamic nuclei in agreement with transcriptomic gene expression data. Immunohistochemistry and studies in
the hypothalamic clonal neuronal cell line, mHypoE-N42 (N42), confirmed that alpha 1-antichymotrypsin (α1AC), the
protein encoded by serpinA3, is localised to neurons and revealed that it is secreted into the media. SerpinA3N
expression in N42 neurons is upregulated by palmitic acid and by leptin, together with IL-6 and TNFα, and all three
genes are downregulated by the anti-inflammatory monounsaturated fat, oleic acid. Additionally, palmitate
upregulation of serpinA3 in N42 neurons is blocked by the NFκB inhibitor, BAY11, and the upregulation of serpinA3N
expression in the hypothalamus by HFD is blunted in IL-1 receptor 1 knockout (IL-1R1−/−) mice.
Conclusions: These data demonstrate that serpinA3 expression is implicated in nutritionally mediated hypothalamic
inflammation.
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Once considered problematic for only the Western, devel-
oped world, the burden of obesity today encompasses most
countries [1], with shifts in global eating patterns causing
detrimental changes in body weight and composition, asso-
ciated diseases and decreased quality of life [2, 3]. The de-
velopment of effective treatments for obesity has not been
fruitful, with the continued futility of dieting methodologies
for sustained weight loss, and gastric surgery being the only
current long-term solution [4–6], putting health care* Correspondence: l.williams@abdn.ac.uk
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for more effective, preventative measures to be put in place,
it is crucial to understand the mechanisms that cause obes-
ity. The overconsumption of energy-dense foods, particu-
larly those high in long-chain saturated fat and sugar,
appears to be a primary driving force behind the obesity
epidemic [7]. These foods have been shown to have a
powerful effect on the hypothalamus in rodent models,
resulting in inflammation and astrogliosis that is implicated
in diet-induced obesity [8–10].
Energy balance, food intake and consequently body weight
are effectively regulated by a well-defined and complex hypo-
thalamic system. Briefly, two distinct types of neurons havele is distributed under the terms of the Creative Commons Attribution 4.0
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orexigenic neurons expressing neuropeptide Y (NPY) and
agouti-related peptide (AgRP) and anorexigenic neurons ex-
pressing proopiomelanocortin (POMC) and cocaine- and
amphetamine-regulated transcript (CART). Both orexigenic
and anorexigenic neurons express leptin receptors, highlight-
ing the importance of this hormones in the system. Leptin
acts on multiple levels in hypothalamic neurons, effecting
gene transcription, post-translational processing as well as
membrane polarisation to inhibit AgRP/NPY neurons while
activating POMC/CART neurons, resulting in a stable body
weight [11]. In the obese state, the ability of leptin to regulate
feeding behaviour as well as peripheral glucose homeostasis
is diminished as a result of hypothalamic insensitivity to this
hormone [12–16].
When animals are fed a high-fat diet (HFD), they ingest
more energy than they expend, resulting in increased adi-
posity, and eventually obesity, suggesting that a HFD com-
promises the hypothalamic systems that regulate food
intake. This has been confirmed in a number of rodent
studies showing that a HFD induces inflammation in the
hypothalamus activating microglia, astrocytes and neurons
via a Toll-like receptor 4 (TLR4)-dependent mechanism
[17–19] and the IKKβ/NFκB and JNK inflammatory path-
ways [20–24] resulting in leptin and insulin insensitivity.
Blocking or inhibiting inflammation in the hypothalamus
prevents leptin and insulin insensitivity and obesity induced
by a HFD [22, 23, 25, 26].
In order to further explore the mechanisms linking
HFD to hypothalamic dysfunction and leptin insensitiv-
ity, we carried out a microarray-based transcriptomics
experiment to determine gene expression changes in re-
sponse to a HFD as well as leptin challenge. One of the
genes that was considerably upregulated by both leptin
and HFD was serpinA3N, the gene encoding the
anti-protease, alpha-1-antichymotrypsin (α1AC). In the
periphery, α1AC is an acute phase protein produced by
hepatocytes [27] and has been recently identified as a
marker of reactive astrogliosis in the brain [28]. In-
creased levels of α1AC in the brain are commonly asso-
ciated with inflammatory conditions such as Alzheimer’s
disease [29, 30].
In the present study we identified, using transcriptomics,
that the gene, serpinA3n, is highly expressed in the hypo-
thalamus and is upregulated by leptin and HFD, a finding
confirmed by semi-quantitative in situ hybridisation. Fur-
thermore, we have shown that nutritional factors, as well
as time on experiment, play a role in the hypothalamic
nuclei-specific regulation of serpinA3N expression. As the
expression of serpinA3N in the periphery has been re-
ported to be dependent on inflammation and IL-1 stimula-
tion [31–34], we tested the effect of HFD on hypothalamic
serpinA3N expression in IL-1 receptor 1 knockout mice
(IL-1R1−/−) and in the hypothalamic clonal neuronal cellline, mHypoE-N42 (N42) which we challenged with oleic
and palmitic acid, the latter, with and without blocking the
NFκB pathway. In IL-1R1−/− mice, HFD challenge failed to
upregulate serpinA3N expression in contrast to wild-type
mice and in N42 cells oleic acid downregulated serpinA3N
while palmitate upregulated expression which was negated
by inhibiting the NFκB pathway, confirming that
HFD-induced expression is dependent on inflammation.
Also, as increased serpinA3N expression in the brain has
previously been identified as a marker of astrocyte activa-
tion [28], we examined α1AC immunoreactivity in the
hypothalamus together with that of glial fibrillary acidic
protein (GFAP), an astrocyte marker, ionised calcium
binding adaptor molecule 1 (Iba1), a microglial marker,
and NPY and AgRP, markers of neurons important in en-
ergy balance. Immunoreactive α1AC cells were larger and
dissimilar to astrocytes and microglia having a distinctive
neuronal shape and close associations with NPY and AgRP
beaded fibres, also pointing to neuronal expression of
serpinA3N. In addition, using Western blotting, the pro-
tein product of serpinA3N, α1AC, was detected in N42
neurons in much lower levels than that found in the media
demonstrating that the protein is secreted. The expression
of serpinA3N in and the secretion of α1AC from these cells
confirmed neuronal expression of serpinA3N.
Results
Transcriptomics
Transcriptomic data revealed the regulation of serpi-
nA3N gene expression in total dissected hypothalamic
tissue from mice maintained on a LFD or HFD for 1 or
4 weeks and either challenged with vehicle or leptin. A
three-way ANOVA showed significant effects of HFD
(P = 0.0007), leptin challenge (P = 2.55 × 10−6), and time
on diet (P = 1.34 × 10−6). However, there was no inter-
action between these factors (Fig. 1). A full list of chan-
ged genes can be found at NCBI’s Gene Expression
Omnibus and is accessible through GEO Series acces-
sion number GSE113943 (https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi).
Localisation of serpinA3N and α1AC in the hypothalamus
In situ hybridisation using a serpinA3N-specific
riboprobe revealed specific labelling throughout the
hypothalamus with particularly high levels of expres-
sion in the arcuate nuclei (ARC), ventromedial
(VMH) and dorsomedial nuclei (DMH). The labelling
extended out to the edges of the lateral hypothal-
amus (LH) (Fig. 2a). Immunoreactive α1AC in the
ARC of the hypothalamus revealed a neuronal
morphology (Fig. 2b–e). Dual staining using an
anti-mouse α1AC antibody (brown) alongside blue
anti-GFAP (astrocyte specific) and anti-Iba1 (micro-
glia specific) staining showed smaller and distinctly
Fig. 1 Data derived from NuGO Affymetrics arrays from the
hypothalamus of C57BL/6J mice maintained on a HFD or LFD for 1
and 4 weeks challenged with IP vehicle or leptin. The log of
serpinA3N gene expression is represented by box and whisker plots.
Three-way ANOVA showed a significant effect of diet, leptin
challenge and time on the diet but no interaction between any of
these factors (n = 10)
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overlapping staining (Fig. 2b, c). Staining with both
anti-NPY and anti-AgRP (blue) showed beaded fibres
closely associated with anti-α1AC-positive neurons
(brown) (Fig. 2d, e).
Regulation of serpinA3N and expression by HFD and time
A robust increase in labelling was seen after just 1 week on
a HFD. It was possible to distinguish distinct hypothalamic
nuclei which expressed high levels of serpinA3N including
the ARC, VMH, DMH, and LH (Fig. 3a, b). Quantification
of hypothalamic nuclei including the ARC, VMH, DMH
(Fig. 3c–e) and LH (not shown) confirmed the increase in
serpinA3N gene expression by a HFD seen intranscriptomics studies. Expression in the ARC was signifi-
cantly increased by around 50% after 4 weeks on the HFD
compared to LFD control (Fig. 3c). In comparison, the level
of gene expression in the VMH and DMH was increased
by approximately 2.5 and 4 times after only 1 week, re-
spectively. After 16 weeks on the HFD, the labelling in
these nuclei had increased to approximately eight times of
that seen in LFD fed mice at week 1 (Fig. 3d, e). Analysis of
the gene expression data by two-way ANOVA confirmed
that serpinA3N gene expression increased with time on the
diet and there was no interaction between diet and time for
the ARC and DMH but there was for the VMH (P < 0.05)
indicating that the age of the animals may also lead to in-
creases in serpinA3N gene expression in the ARC, VMH
and DMH over the 16 weeks of the experiment (Fig. 3c–e).
Regulation of serpinA3N expression by leptin
To further investigate the regulation of serpinA3N by
leptin, in situ hybridisation was carried out on both
leptin-deficient mice (ob/ob) and mice lacking functional
leptin receptors (db/db) and their lean littermates
(Fig. 4a–d). Images from ob/ob, db/db and lean mice
show a much lower level of serpinA3N gene expression
in ob/ob and db/db mice (Fig. 4a, b). Quantification of
labelling showed a difference of the order of seven to ten
times lower levels of gene expression in db/db and ob/ob
mice compared to their lean littermates (Fig. 4c, d).
Treatment of ob/ob mice with leptin (10 mg/ml injected
IP) resulted in a time-dependent increase in serpinA3N
expression with a 10-fold increase within 1 h and a
14-fold increase after 4 h (Fig. 4e). While leptin challenge
in lean mice did not increase serpinA3N levels of expres-
sion above basal after 1 h, leptin challenge did increase
levels of expression significantly after 4 h but only by
approximately 70% (Fig. 4f) compared to the 14-fold
increase seen in ob/ob mice 4 h after leptin challenge.
Regulation of serpinA3N expression by HFD in the
absence of leptin
Transcriptomics data indicated that the effects of leptin
and HFD were independent. To confirm this, ob/ob mice,
lacking leptin, were fed either a LFD (10% of calories from
fat), or a HFD (45% or 60% of calories from fat). The HFD
led to a large increase in serpinA3N gene expression com-
pared to the LFD in the nuclei expressing the gene. Quanti-
fication of labelling showed an increase of around 20–30
times in both the ARC and the VMH after 8 weeks on a
HFD (Fig. 5a, b).
Regulation of serpinA3N expression by fasting and
refeeding
In mice fasted for 24 h, serpinA3N expression increased
throughout the hypothalamus. Expression increased by
around 40% in the ARC and 200% in the VMH.
AB C
D E
Fig. 2 a Representative in situ autoradiograph of a C57BL/6J mouse
brain section after 4 weeks of HFD showing serpinA3N expression in
the arcuate nuclei (ARC), the ventromedial nuclei of the
hypothalamus (VMH), the dorsomedial nuclei of the hypothalamus
(DMH) and the lateral hypothalamus (LH). b–e Representative
immunostaining of α1AC (brown) and b GFAP, c Iba1, d AgRP and e
NPY (all blue) in the arcuate nuclei after 1 week of HFD. Bar = 20 μm
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to those seen in the fed animals (Fig. 6a, b).
Regulation of serpinA3N by HFD in IL-1R1−/− mice
Feeding IL-1R1−/− mice, a HFD for 8 weeks appeared to in-
crease serpinA3N by a relatively small amount in the ARC,
VMH and DMH compared to the effects seen in wild-type
mice. There was substantial variability in the response to the
HFD which failed to reach statistical significance (Fig. 7a–c).Regulation of SerpinA3N in N42 cultured hypothalamic
neurons
Leptin challenge upregulated serpinA3N gene expression by
twofold compared to vehicle-treated N42 neurons. IL-6 and
TNFα were also upregulated. A similar effect was induced
by 200 μM palmitic acid. In comparison, 200 μM oleic acid
downregulated the gene expression of all three genes
(Fig. 8a–c). The upregulation of serpinA3N, IL-6 and TNFα
gene expression by palmitate was significantly reduced in
the presence of the NFκB inhibitor, BAY11 (Fig. 8d–f).
α1AC secretion from N42 cultured neurons
SDS-PAGE gels of media from cultured N42 neurons
showed the presence of several protein bands of dif-
ferent molecular weights but not in cell free media
(Fig. 9). Using Western blotting, cell free media dis-
played extremely faint immunoreactive α1AC bands
but culture media from N42 neurons showed two
immunoreactive bands, the lower at 59 kDa corre-
sponding to the molecular weight of α1AC (positive
control). The band above may correspond to a dif-
ferent post-translationally modified form of the pro-
tein. The cell lysate in contrast showed only
extremely faint immunoreactive bands including one
at 59 kDa (Fig. 9).
Discussion
Hypothalamic inflammation in response to a HFD in ro-
dents is well-documented after both short- and
long-term exposure to HFD [17–19, 35, 36]. In the
present study transcriptomics data show that, a so far
unreported gene, associated with inflammation in the
periphery, serpinA3N, is strongly upregulated by HFD
and leptin in the hypothalamus. An incidental finding is
that serpinA3N is also upregulated by time on experi-
ment which corresponds to the increasing age of the
mice. Surprisingly, these effects were largely independent
of one another indicating that while hypothalamic serpi-
nA3N expression is regulated by a number of factors
these appear to act via independent pathways.
It can be difficult to differentiate between the effects
of a HFD and that of diet-induced obesity as the former
rapidly leads to the latter. In the present study, the ef-
fects of obesity and a HFD are separated in obese ob/ob
mice, which, though obese, normally have relatively low
levels of hypothalamic serpinA3N gene expression, but
when challenged with a HFD, the level of expression is
rapidly upregulated demonstrating that the level of serpi-
nA3N expression is regulated by a HFD rather than
obesity per se. Also, the possibility that increased caloric
intake rather than diet composition is responsible for
the upregulation of serpinA3N cannot be ruled out com-
pletely in our animal studies. However, ob/ob mice are





Fig. 3 Representative in situ autoradiographs of C57BL/6J mouse brain sections showing serpinA3N expression in a LFD-fed mouse and b HFD-
fed mouse. Levels of serpinA3N gene expression in LFD- and HFD-fed mice measured by semi-quantitative in situ hybridisation c in the arcuate
nuclei (ARC), d the ventromedial nuclei of the hypothalamus (VMH) and e the dorsomedial nuclei of the hypothalamus (DMH). Two-way ANOVA
showed a significant effect of diet P < 0.001 for the ARC, VMH and DMH and time P < 0.001 for the VMH and P < 0.05 for the ARC and DMH with
an interaction between diet and time P < 0.05 for the VMH only. One-way ANOVA showed differences between HFD and LFD from 4 weeks
onwards for the ARC and for all times tested for the VMH and DMH. *P < 0.05, **P < 0.01, ***P < 0.001 (n = 6)




Fig. 4 Representative in situ autoradiographs of mouse brain sections showing serpinA3N expression in a ob/ob mouse on a C57BL/6J
background and b lean C57BL/6J mouse. Levels of serpinA3N gene expression in the arcuate nuclei measured by semi-quantitative in situ
hybridisation of c db/db on a C57BL/6J background and lean C57BL/6J mice, d ob/ob and lean mice, e ob/ob mice injected with IP vehicle (veh.)
or leptin after either 1 or 4 h (h) and f lean mice injected with IP vehicle (veh.) or leptin after either 1 or 4 h (h). *** P < 0.001 (n = 6)
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to a HFD. Additionally, the pro-inflammatory long-chain
saturated fat, palmitic acid, upregulates expression of
serpinA3N in the clonal neuronal cell line N42, while
oleic acid, an anti-inflammatory monounsaturated fattyacid, decreases gene expression indicating that fatty
acids have a direct effect on serpinA3N expression in
neurons, supporting the contention that serpinA3N ex-
pression responds to the increased long-chain saturated
fat in the diet rather than to increased caloric intake.
A B
Fig. 5 Levels of serpinA3N gene expression measured by semi-quantitative in situ hybridisation in the a arcuate nuclei (ARC) and b ventromedial
nuclei of the hypothalamus (VMH) of ob/ob mice fed either a LFD, 10% energy (kCal) from fat, or HFD either 45% or 60% energy (kCal) from fat
for 8 weeks. ***P < 0.001 (n = 6)
A B
Fig. 6 Levels of serpinA3N gene expression measure by semi-quantitative in situ autoradiography in the a arcuate nuclei (ARC) and b
ventromedial nuclei of the hypothalamus (VMH) of C57Bl/6J mice either fed, fasted for 24 h or refed for 24 h. *P < 0.05, **P < 0.01 (n = 8)
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A B C
Fig. 7 Levels of serpinA3N gene expression measured by semi-quantitative in situ autoradiography in the a arcuate nuclei (ARC), b ventromedial
nuclei of the hypothalamus (VMH) and c dorsomedial nuclei of the hypothalamus (DMH) in IL-1R1−/− mice on a C57BL/6J background fed either a
LFD or HFD for 8 weeks (n = 9 for HFD and n = 5 for LFD)
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nA3N, serves as an acute phase protein produced by the
liver, in response to inflammation and binds to proteases,
thus limiting inflammation-related damage [37, 38]. In the
brain, α1AC has been shown to be associated with inflam-
mation and elevated levels are found in Alzheimer’s dis-
ease, closely linked with amyloid plaques [38–40]. Other
observed functions of peripheral α1AC include inhibition
of oxygen uptake and superoxide generation in granulo-
cytes [41], DNA binding independent of its anti-protease
activity, regulation of its own gene expression, and inhib-
ition of DNA polymerase and DNA primase activity [42,
43]. However, the target protein for, and the function of,
α1AC in the hypothalamus remains to be identified.
In the present study, in situ hybridisation revealed a
widespread localisation of serpinA3N expression through-
out the hypothalamus in a pattern corresponding to major
nuclei indicating that the expression is neuronal. This is
further supported by immunohistochemistry where dual
immunostaining for α1AC and both the astrocyte marker,
GFAP, and the microglial marker Iba1 reveal no overlap in
staining and immunopositive α1AC show a characteristic
neuronal shape which is both larger and distinctly differ-
ent from that of GFAP and Iba1 immunopositive cells.
Dual staining with NPY and AgRP shows close associa-
tions between α1AC immunopositive fibres and NPY and
AgRP beaded fibres. Also, in N42 clonal neurons in cul-
ture, which have been used previously to investigate hypo-
thalamic control mechanisms [44], the expression of
serpinA3N is upregulated by both leptin and palmitate ina manner consistent with that seen in the hypothalamus
in response to leptin challenge and a HFD. Taking all of
this evidence together, serpinA3N measured in the present
study appears largely neuronal in origin. Nonetheless, in a
previous genomic study involving two mouse models of
brain injury (ischemic stroke and neuroinflammation), ser-
pinA3N was identified as a marker of reactive astrogliosis
[28], and as HFD has been shown to induce astrogliosis in
mice [17, 45], then potentially, some of the increase in ser-
pinA3N expression may be astrocytic. Thus, we cannot
rule out that part of the increased gene expression seen
may occur in astrocytes.
In the liver, increased levels of serpinA3N gene expres-
sion and subsequently increased levels of α1AC, like all
acute phase proteins, are stimulated by inflammation, par-
ticularly by raised circulating levels of IL-6 and IL-1 type
cytokines working via STAT3 activation and increased
NFκB [46]. In N42 neurons, both IL-6 and TNFα were up-
regulated in parallel with serpinA3N by leptin and palmitic
acid, with palmitic acid stimulated gene expression inhib-
ited by BAY11 blocking the NFκB pathway. These results
together with the lack of HFD-induced serpinA3N upregu-
lation in IL-1R1−/− mice clearly indicated that hypothal-
amic serpinA3N is involved in the inflammatory response
as in the periphery.
Leptin stimulates the release of IL-1β in the hypothal-
amus [47] while a HFD does not appear to upregulate
IL-1β in this brain area [17] but IL-1β does increase in the
periphery in obesity [48] indicating a more complex
relationship between HFD, IL-1β and serpinA3N
A B C
D E F
Fig. 8 a–f In mHypoE-N42 cells, a–c SerpinA3N, IL-6 and TNFα gene expression were all upregulated by leptin and palmitic acid challenge and
downregulated by oleic acid. d–f The upregulation of SerpinA3N, IL-6 and TNFα gene expression by palmitic acid was blocked by the NKκB
inhibitor BAY11. P < 0.05, ***P < 0.001, **P < 0.01. NS not significant
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the blood-brain barrier but influence the brain via inter-
mediate mechanisms [49]. The source of the interleukins
and the mechanisms underlying upregulation of serpi-
nA3N expression by a HFD requires further investigation.
While there is no significantly different upregulation of
serpinA3N gene expression in IL-1R1−/− mice, there is an
indication of a variable response to HFD which may be
due to increases in circulating leptin levels in response to
increasing adiposity and, thus, increasing leptin levels.
While in the absence of leptin, signalling levels of serpi-
nA3N expression in the hypothalamus are low and leptin
challenge upregulates serpinA3N expression, the localisa-
tion and pattern of leptin-stimulated expression differs
from that induced by a HFD. Leptin-induced serpinA3N
expression increases mainly in the ARC, VMH and
throughout the hypothalamus up to the borders of the LH
with no clear demarcation of hypothalamic nuclei otherthan the ARC and VMH. The role of leptin in the stimula-
tion of serpinA3N expression on a HFD, however, appears
to be relatively small as a HFD upregulates serpinA3N
gene expression to a much greater degree in ob/ob mice,
in the absence of leptin, compared to lean mice in the
presence of leptin. The reasons for this are not clear, but
counterintuitively, it may be that the presence of leptin is
somehow protective against the induction of serpinA3N
gene expression by a HFD. Leptin receptors are present
on both neurons and astrocytes and leptin may be upregu-
lating serpinA3N in either or both these cell types [50],
with the upregulation of serpinA3N in N42 hypothalamic
neurons confirming the neuronal regulation of serpinA3N
by leptin. Nonetheless, circulating leptin levels do not ap-
pear to be a major regulator of serpinA3N gene expression
in the fasting and refed states as the regulation or serpi-
nA3N occurs in opposition to circulating leptin levels,
with fasting, which causes leptin levels to drop, increasing
Fig. 9 Representative SDS PAGE gel and immunoblot showing
alpha-1-antichymotrypsin (α1AC), secreted into the media from N42
neuronal cells. No bands are visible with media alone. The blot
shows two immunoreactive bands in the media from N42 neurons
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creases circulating leptin levels [51], results in decreased
serpinA3N gene expression. However, this may be ex-
plained by the stimulation of serpinA3N gene expression
by the increased levels of circulating free fatty acids which
occur during fasting [52].
Leptin insensitivity, induced by a HFD, is well docu-
mented [22]. While this concept was not specifically
tested in the present study, the transcriptomics data
which combined leptin challenge on a LFD and HFD in-
dicated that the effect of diet was separate from that of
leptin challenge and that there was no interaction be-
tween the two indicating that upregulation of serpinA3N
gene expression by leptin is unaffected by HFD; however,
this remains to be specifically tested.
Increased time on experiment or age of the mice also
appears to be a factor in the upregulation of serpinA3N
gene expression in the ARC, VMH and DMH of the hypo-
thalamus. Although the effects of extreme ageing were not
investigated in the present study, the mice were older at
the end of both the transcriptomics and the in situ hybrid-
isation studies on HFD than at the beginning and both
showed a clear effect on serpinA3N gene expression with
time despite being measured by different approaches. The
mice exposed to the HFD for the longest period of timevaried in age between 12 weeks at the beginning of the
study and 28 weeks at the end on the study. Twelve weeks
of age corresponds to a young mature adult, and 28 weeks
corresponds to early middle age with mice showing some
signs of age-related changes [53]. Ageing has also been re-
ported to induce inflammation in the hypothalamus via
the IKKβ/NFκB pathway. Indeed, hypothalamic inflamma-
tory changes have shown to control systemic ageing dem-
onstrating the importance of this phenomenon to the
health of the whole organism [54].
Conclusions
We have shown the upregulation of a novel hypothal-
amic gene, serpinA3N, by HFD and leptin. Increasing
age and fasting also resulted in an upregulation although
to a lesser extent. The upregulation of serpinA3N ex-
pression by leptin and palmitic acid was confirmed in
N42 neurones in culture along with the upregulation of
IL-6 and TNFα, two classical markers of inflammation.
Blocking the NFκB inflammatory pathway by BAY11 not
only prevented the upregulation of IL-6 and TNFα, but
also that of serpinA3N. The protein product of serpi-
nA3N, α1AC, is found in the media from cultured N42
neurons but is difficult to visualise within the cell lysate
indicating that α1AC is a secreted protein in the hypo-
thalamus as it is in the periphery.
These data strongly support the contention that serpi-
nA3N expression is a marker of inflammation in the
hypothalamus regulated by nutritional status and leptin
and indicate a potential role for α1AC in hypothalamic
inflammation and the regulation of energy balance.
Methods
Animal studies
All experiments were carried out according to the institu-
tional and national guidelines of the European Convention
of Vertebrate Animals Used for Experimentation, under
European Council Directive 86/609/EEC dated November
1986. For the transcriptomics studies, male, 16-week-old,
C57BL/6J mice were obtained from Charles River labora-
tories (Maastricht, The Netherlands) and housed in pairs
in the light- and temperature-controlled animal facility of
Wageningen University (12:12-h light/dark cycle at 22 °C).
Mice were maintained for 1 or 4 weeks on either a HFD
(45% kCal from fat) or LFD (10% kCal from fat) (Research
Diet Services BV, Wijk bij Duurstede, The Netherlands)
modelled on (D12451 and D12450B respectively Research
Diets, NJ, USA). (Please see https://researchdiets.com/
opensource-diets/dio-series-diets for diet composition de-
tails). For this study, palm oil was used in place of lard.
They were then challenged with three intraperitoneal (IP)
injections of murine leptin (2 mg/kg body weight) (R&D
Systems, Abingdon, UK) or carrier at 24, 15 and approxi-
mately 3 h prior to killing in the early morning (n = 10).
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To further investigate the regulation of serpinA3N gene
expression on a HFD, male C57BL/6J mice (Harlan, Bice-
ster, UK), aged 12 weeks, were singly housed on grid floors
and fed either a HFD (60% kCal from fat) or a LFD (10%
kCal from fat) (D12452 and D12450B respectively, Re-
search Diets, NJ, USA—see web site above for detailed
dietary breakdown), ad libitum for 3 days, 1, 4, 8, 12 or
16 weeks and killed either by exsanguination or by perfu-
sion fixation (1 week) with 4% paraformaldehyde in phos-
phate buffered saline (PBS) under terminal anaesthesia
(n = 6). To further investigate the upregulation of serpi-
nA3N by leptin, male mice on the C57BL/6J background
either leptin deficient (ob/ob) or lacking functional leptin
receptors (db/db) and their lean littermates (Harlan, Bice-
ster, UK) were killed for in situ hybridisation (n = 6).
Leptin-deficient ob/ob mice and lean littermates (n = 6)
were also challenged with vehicle or leptin by intraperito-
neal (IP) injection (2 mg/kg body weight) and killed either
1 or 4 h later as detailed above. Food intake in response to
leptin was not measured at this time because any changes
were deemed to be impractical to measure with any accur-
acy due to the fact that leptin challenge was carried out
over such a short period of time during the light period
when food intake is already low. To confirm the upregula-
tion of serpinA3N expression by HFD is independent from
that of leptin, ob/ob mice were fed either a LFD 10% kCal
from fat or a HFD either 45% or 60% kCal from fat in the
form of lard (diets detailed above) for 8 weeks prior to kill-
ing by exsanguination.
To test the effect of nutritional status on hypothalamic
serpinA3N gene expression, C57BL/6J mice were fasted
for 24 h or fed ad libitum on standard mouse diet prior
to killing. Refed animals were allowed access to food ad
libitum for a period of 24 h after fasting (n = 8).
To test the possibility that inflammation plays a role in
the effect of HFD on the expression of serpinA3N, mice
from IL-1R1−/− breeding pairs, on C57BL/6J background,
purchased from Jackson laboratories were bred at Univer-
sity College Dublin (UCD) for 6–10 generations under
specific pathogen-free conditions. Male IL-1R1−/− mice
were then fed HFD, 45% kCal or LFD, 10% kCal from fat
for 12 weeks prior to killing (D12451 and D12450B re-
spectively, Research Diets, NJ, USA). In this study, palm
oil was used instead of lard (n = 9 HFD and n = 5 chow).
Transcriptomics
Hypothalami were dissected and snap-frozen in liquid ni-
trogen and stored at − 80 °C until RNA extraction. Total
RNA was extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA), and the mRNA purified with RNeasy Mini
Kit (Qiagen, Venlo, The Netherlands) with 1% β-mercapto
ethanol and treated with DNAse. The mRNA integritywas checked on an Agilent 2100 Bioanalyzer (Agilent
Technologies, Amsterdam, The Netherlands) (average
RIN 9.2), and individual RNA samples (4 μg per animal)
were labelled and hybridised on a Affymetrix NuGO
mouse array as described previously [35].
In situ hybridisation
The riboprobe for serpinA3N, accession no. BC013651,
was derived using the forward primer 5′CTACGCGGG
CAAGAGGA3′ and the reverse primer 5′AAGG
GGGCAATTTCAGTTT3′. The size of the amplified in-
sert was 543 bp. Automated sequencing was performed
to verify the probe sequence.
Messenger RNA levels were quantified by in situ hybridisa-
tion, on 20-μm thick coronal hypothalamic cryo-sections,
using techniques described in detail elsewhere [56]. Briefly,
slides were fixed in 4% (w/v) paraformaldehyde in 0.1 mol/l
PBS for 20 min at room temperature, washed in PBS, incu-
bated in 0.1 mmol/l triethanolamine for 2 min and acetylated
in 0.1 mmol/l triethanolamine and 0.25% (v/v) acetic anhyd-
ride for 10 min. Sections were dehydrated in ethanol and
dried under vacuum before hybridisation with riboprobes at
106 cpm/ml for 18 h at 58 °C. After hybridisation, sections
were desalted through a series of washes in standard saline
citrate (SSC) to a final stringency of 0.1× SSC at 60 °C for
30 min, treated with RNase A and dehydrated in ethanol.
Slides were apposed to Biomax MR (Sigma-Aldrich, UK) to-
gether with [14C] micro-scale standards (Amersham Inter-
national, Amersham, UK) at room temperature for varying
lengths of time depending on the probes used to ensure that
the optical density of areas to be measured fall within the lin-
ear region of the standard curve.
Autoradiographs were scanned on a Umax Power Look
II (UMAX Data Systems, Fremont, CA, USA). Integrated
optical densities (IOD) of specific nuclei were quantified
with reference to a mouse brain atlas [57] using the Image
Pro-plus system (Media Cybernetics, Silver Springs, MD,
USA). IOD was converted to nCi/g using [14C] microscale
standard curves for measures of total gene expression.
Immunohistochemistry
Frozen sections (20 μm) were first incubated with goat
anti-mouse serpinA3N (R&D Systems cat. no. AF4709) at
a dilution of 1:1000 overnight at 4 °C then incubated for
30 min at room temperature with biotinylated anti-goat
IgG (Vector Labs cat. no. PK-6105) according to the man-
ufacturer’s instructions followed by ABC reagent (Vector
Labs cat. no. PK-6105) and stained with 3,3′-diaminoben-
zidine (DAB) substrate solution (brown) (Vector Labs cat.
no. SK-4100). Sections were then thoroughly washed and
incubated with either chicken anti-GFAP (Millipore, UK
cat. no. AB5541), rabbit anti-IbA1 (Wako cat. no.
019-19741), rabbit anti-NPY (ThermoFisher Scientific cat.
no. PA5-19568) or rabbit anti-AgRP (Phoenix
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overnight at 4 °C and then at room temperature for
30 min with either goat anti-chicken IgG (Vector Labs
cat. no. BA-9010) at a dilution of 1:200 followed by Vec-
tastain Elite ABC kit (goat IgG) (Vector Labs cat. no.
PK-6105) or directly with the Vectastain Elite ABC kit
(goat IgG) and stained with Vector SG (blue) (Vector Labs
cat. no. SK-4700). Control sections omitted the primary
antibodies.
Neuronal culture and reagents
To investigate the regulation of serpinA3N gene expression
specifically in neurons, the embryonic immortalised hypo-
thalamic cell line, N42, was used (Cellution Biosystems Inc.,
Ontario, Canada. Please see https://www.cedarlanelabs.com/
Products/Detail/CLU122 for a comprehensive list of all genes
expressed by these cells including the leptin receptor). These
cells have been previously shown to provide a good model
for hypothalamic neuron gene expression studies [44].
Cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Life Technologies, Paisley, UK) sup-
plemented with 10% fetal bovine serum and 1% penicil-
lin/streptomycin (Life Technologies) maintained at 37 °C
under 5% CO2. Neurons were grown in 60-mm plates
(n = 6) to 90% confluence then challenged with either
50 nM leptin (R&D Systems, Abingdon, UK), 200 μM
palmitic acid or 200 μM oleic acid conjugated to fatty
acid-free bovine serum albumin (BSA) (Sigma-Aldrich,
UK), or the appropriate vehicle as a control. For leptin,
this was a mixture of 12 μM HCl and 6 μM NaOH and
for fatty acids 50 μM fatty acid-free BSA. To inhibit the
NFkB pathway, N42 neurons were treated with 50 μM
BSA or 200 μM palmitate in the presence and absence of
25 μM of the NFkB inhibitor BAY 11-7082 (Cayman
Chemical, UK). All solutions were filter sterilised prior to
use. For all treatments, medium was removed after 6 h.
Real-time PCR
After the challenge, the medium was removed and cells
were lysed using RLT lysis buffer (RNeasy Mini Kit Qia-
gen, Venlo, The Netherlands). Cell lysates were then col-
lected and RNA extracted using an RNeasy Mini Kit
(Qiagen) following the manufacturer’s instructions. RNA
integrity was assessed by an Agilent 2100 Bioanalyzer
(Agilent Technologies, Amsterdam, The Netherlands).
One microgram of total RNA was reverse transcribed to
generate cDNA using Superscript II reverse transcriptase
(Life Technologies, CA, USA). Real-time PCR was car-
ried out using Taqman Fast Universal PCR master mix
(Applied Biosystems, USA) according to manufacturer’s
instructions using the following Taqman assays: B2M
(Mm00437762_m1), serpinA3N (Mm00776439_m1),
IL-6 (Mm00446190_m1) and TNFα (Mm00443258_m1).
Each reaction used 1 μL of cDNA template.Western blotting
N42 neurons were grown as described earlier. The cell cul-
ture medium was collected and protein concentrated using
an Amicon Ultra-0.5 Centrifugal Filter (10 K device, Milli-
pore, UK). For lysate preparation, cells were scraped into
1 ml of PBS and pelleted by centrifugation; 1 ml of M-PER
mammalian protein extraction reagent (Thermo scientific)
was added to the cell pellet before sonication using a Sanyo
Soniprep 1500 to ensure complete cell lysis. Protein
concentrations were determined using the Pierce 660 nm
protein assay reagent (Thermo Scientific). Samples were
then diluted 3:1 with 4× Laemmli sample buffer (Bio-Rad,
UK) with 2-mercaptoethanol (9:1 ratio) and boiled for
10 min, and 2 μg of protein was loaded on the gels. For
media in which no cells were cultured, used as a control, an
amount equivalent to 5 μL of concentrated media was
loaded and as a positive control 12.5 ng of recombinant
mouse serpin α1AC protein (R&D Systems). Proteins were
separated on 10% mini-PROTEANTGX Precast Gels
(Bio-Rad) and transferred to a PVDF Membrane (Bio-Rad)
before immuno-detection using goat anti-mouse serpi-
nA3N (R&D Systems) and peroxidase-linked secondary
antibody (Donkey polyclonal antibody to goat IgG (HRP),
abcam, UK). Chemiluminescent signal on the blots was de-
tected using a Fujifilm LAS-3000 Imager after incubation
with Clarity Western ECL substrate kit (Bio-Rad) using the
manufacturer’s recommended protocol. Additional gels
were run in parallel and stained with Colloidal Coomassie
Blue (Safe Stain) (Severn Biotech Ltd) in order to visualise
total protein present in cell media and lysates.
Statistical analysis
Data are presented as mean ± SEM and were analysed
using GenStat (GenStat, Eighth Edition (2005), VSN Inter-
national Ltd., Oxford). In the case of experiments testing
the influence of a single factor, a one-way ANOVA was
performed. Where two or three factors were compared in
a single experiment, a two- or three-way ANOVA
followed by post hoc Student’s t tests based on the LSD
were performed. In this case, the ANOVA results are
expressed in the figure legend and the results of the
Student t test are represented on the graph. P < 0.05 was
considered statistically significant.
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